Email updates

Keep up to date with the latest news and content from Critical Care and BioMed Central.

Commentary

CXCR3 blockade: a novel anti-sepsis approach?

Matthew J Delano and Lyle L Moldawer*

Author Affiliations

Department of Surgery, University of Florida, College of Medicine, Gainesville, Florida 32610, USA

For all author emails, please log on.

Critical Care 2012, 16:176  doi:10.1186/cc11818


See related research by Herzig et al., http://ccforum.com/content/16/5/R168

Published: 21 November 2012

Abstract

Blockade of the CXC chemokine receptor 3 (CXCR3) attenuates inflammation and improves survival in a murine model of near lethal polymicrobial sepsis. However, given the multitude of cellular responses and inflammatory mediators that orchestrate sepsis syndrome, more detailed investigations will be required before a complete understanding of the mechanism(s) of CXCR3 blockade and its therapeutic potential are revealed.